PRESS Act
Introduced April 30, 2026 · Last action April 30, 2026
Plain English Summary
This bill amends the Controlled Substances Act to make it illegal to manufacture or distribute pill press machines, encapsulating machines, and related equipment if the person knows or intends them to be used to make counterfeit controlled substances for import into the United States. It also establishes criminal penalties of up to 8-15 years in prison for violating these new rules, depending on the quantity of materials involved.
Who benefits
Law enforcement agencies (DEA, FBI, Customs and Border Protection), federal prosecutors, and pharmaceutical companies whose branded products are counterfeited. Countries and foreign manufacturers who do not produce pill press equipment for illicit purposes face no new costs.
Who pays / loses
Foreign manufacturers and distributors of pill press machines and encapsulating equipment who knowingly sell to drug trafficking operations; domestic importers and distributors who acquire such equipment intending it for counterfeit drug production; criminal organizations operating pill press operations targeting the U.S. market; individuals convicted under the new provisions face up to 8-15 years in federal prison.
Funding & Lobbying Interests
Pharmaceutical manufacturers and brand-name drug makers have a financial interest in reducing counterfeit pill production, as counterfeits divert sales and expose them to liability. Law enforcement and federal agencies benefit from expanded criminal jurisdiction. Foreign machinery manufacturers with legitimate industrial customers (tablet manufacturers, supplement producers, veterinary medicine producers) have no direct financial stake in the bill's passage, though those selling to known illicit operators face enforcement risk.
Political Impact
Affected Groups
Individuals and criminal organizations engaged in large-scale counterfeit pill production and distribution (typically related to opioids, stimulants, and benzodiazepines); foreign manufacturers of pill press equipment in jurisdictions with weak enforcement; U.S. pharmaceutical companies and their shareholders who lose revenue to counterfeits; federal law enforcement personnel who gain expanded investigative authority. The bill does not quantify the scope of the counterfeit pill problem by number of victims or pills seized.
Political Subtext
Proponents frame this as closing a gap in drug trafficking law enforcement by targeting the equipment supply chain for synthetic counterfeit drugs, particularly counterfeit opioids and fentanyl-laced pills that cause overdose deaths. Critics might argue the bill casts an expansibly broad net by penalizing manufacture or distribution based on knowledge or 'reasonable cause to believe,' which could ensnare legitimate industrial equipment suppliers or create prosecutorial discretion issues. The bill does not cite specific instances of successfully prosecuted pill press equipment trafficking that would justify the expanded jurisdiction, nor does it provide data on the scale of equipment-driven counterfeit production. Non-partisan evidence on the effectiveness of supply-side drug equipment controls is limited; most drug policy research focuses on demand reduction and treatment.
Real-World Stakes
If enacted, foreign and domestic manufacturers selling pill press equipment will face heightened compliance obligations and liability exposure if their customers are later discovered to be illicit operators. Federal prosecutors gain new tools to prosecute equipment suppliers upstream of drug manufacturing. The 8-15 year sentencing range aligns the equipment offense with serious drug trafficking penalties. Analogous supply-chain restrictions exist in the Precursor Chemical Act (which restricts List I and List II chemicals used in drug manufacturing), but enforcement has been inconsistent and supply-side controls alone have not significantly reduced illicit drug production. The bill does not cite CBO cost estimates, GAO findings, or evidence that equipment restrictions have reduced counterfeit pill supply in jurisdictions that implemented them. The 'reasonable cause to believe' standard in subsection (c) may create ambiguity in enforcement, as manufacturers of industrial tablet presses serve legitimate pharmaceutical, nutraceutical, and veterinary industries.
Sponsor
Co-sponsors (5)
RSen. Scott, Rick [R-FL]RSen. Grassley, Chuck [R-IA]RSen. Kennedy, John [R-LA]RSen. Crapo, Mike [R-ID]RSen. Ricketts, Pete [R-NE]
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
No campaign finance data available yet.
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.